Roche Reveals Impact Of Multisource Biosimilar Competition
Avastin, Rituxan and Herceptin All Face Challengers
With biosimilars to Avastin on the way later this year in Europe, Roche will face competition to its three key biosimilar monoclonal antibodies in the US, EU and Japan. Management detailed to investors the company’s latest expectations.
